170 related articles for article (PubMed ID: 25991675)
21. High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.
Jacquemier J; Bertucci F; Finetti P; Esterni B; Charafe-Jauffret E; Thibult ML; Houvenaeghel G; Van den Eynde B; Birnbaum D; Olive D; Xerri L
Int J Cancer; 2012 Jan; 130(1):96-104. PubMed ID: 21328335
[TBL] [Abstract][Full Text] [Related]
22. P-cadherin and vimentin are useful basal markers in breast cancers.
Tsang JY; Au SK; Ni YB; Shao MM; Siu WM; Hui SW; Chan SK; Chan KW; Kwok YK; Chan KF; Tse GM
Hum Pathol; 2013 Dec; 44(12):2782-91. PubMed ID: 24139214
[TBL] [Abstract][Full Text] [Related]
23. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
24. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.
Győrffy B; Benke Z; Lánczky A; Balázs B; Szállási Z; Timár J; Schäfer R
Breast Cancer Res Treat; 2012 Apr; 132(3):1025-34. PubMed ID: 21773767
[TBL] [Abstract][Full Text] [Related]
25. A Novel 18-Marker Panel Predicting Clinical Outcome in Breast Cancer.
Biermann J; Nemes S; Parris TZ; Engqvist H; Rönnerman EW; Forssell-Aronsson E; Steineck G; Karlsson P; Helou K
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1619-1628. PubMed ID: 28877888
[No Abstract] [Full Text] [Related]
26. Sense-antisense gene-pairs in breast cancer and associated pathological pathways.
Grinchuk OV; Motakis E; Yenamandra SP; Ow GS; Jenjaroenpun P; Tang Z; Yarmishyn AA; Ivshina AV; Kuznetsov VA
Oncotarget; 2015 Dec; 6(39):42197-221. PubMed ID: 26517092
[TBL] [Abstract][Full Text] [Related]
27. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.
Cai J; Tian AX; Wang QS; Kong PZ; Du X; Li XQ; Feng YM
Cancer Lett; 2015 Oct; 367(2):129-37. PubMed ID: 26210254
[TBL] [Abstract][Full Text] [Related]
28. AGR2 and AGR3 play an important role in the clinical characterization and prognosis of basal like breast cancer.
de Moraes CL; Cruz E Melo N; Valoyes MAV; Naves do Amaral W
Clin Breast Cancer; 2022 Feb; 22(2):e242-e252. PubMed ID: 34462207
[TBL] [Abstract][Full Text] [Related]
29. Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues.
Cimino D; Fuso L; Sfiligoi C; Biglia N; Ponzone R; Maggiorotto F; Russo G; Cicatiello L; Weisz A; Taverna D; Sismondi P; De Bortoli M
Int J Cancer; 2008 Sep; 123(6):1327-38. PubMed ID: 18561318
[TBL] [Abstract][Full Text] [Related]
30. What is the difference between triple-negative and basal breast cancers?
Seal MD; Chia SK
Cancer J; 2010; 16(1):12-6. PubMed ID: 20164685
[TBL] [Abstract][Full Text] [Related]
31. Claudin 1 expression in basal-like breast cancer is related to patient age.
Blanchard AA; Ma X; Dueck KJ; Penner C; Cooper SC; Mulhall D; Murphy LC; Leygue E; Myal Y
BMC Cancer; 2013 May; 13():268. PubMed ID: 23721519
[TBL] [Abstract][Full Text] [Related]
32. Molecular insights on basal-like breast cancer.
Valentin MD; da Silva SD; Privat M; Alaoui-Jamali M; Bignon YJ
Breast Cancer Res Treat; 2012 Jul; 134(1):21-30. PubMed ID: 22234518
[TBL] [Abstract][Full Text] [Related]
33. LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications.
Han YJ; Boatman SM; Zhang J; Du XC; Yeh AC; Zheng Y; Mueller J; Olopade OI
Sci Rep; 2018 Oct; 8(1):15572. PubMed ID: 30349062
[TBL] [Abstract][Full Text] [Related]
34. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
35. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
Acharya CR; Hsu DS; Anders CK; Anguiano A; Salter KH; Walters KS; Redman RC; Tuchman SA; Moylan CA; Mukherjee S; Barry WT; Dressman HK; Ginsburg GS; Marcom KP; Garman KS; Lyman GH; Nevins JR; Potti A
JAMA; 2008 Apr; 299(13):1574-87. PubMed ID: 18387932
[TBL] [Abstract][Full Text] [Related]
36. SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.
Chan HJ; Li H; Liu Z; Yuan YC; Mortimer J; Chen S
Oncotarget; 2015 Sep; 6(28):25815-27. PubMed ID: 26158350
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy.
Kreike B; Halfwerk H; Kristel P; Glas A; Peterse H; Bartelink H; van de Vijver MJ
Clin Cancer Res; 2006 Oct; 12(19):5705-12. PubMed ID: 17020974
[TBL] [Abstract][Full Text] [Related]
38. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.
Khan SS; Karn T; Symmans WF; Rody A; Müller V; Holtrich U; Becker S; Pusztai L; Hatzis C
Breast Cancer Res Treat; 2015 Feb; 149(3):789-97. PubMed ID: 25651779
[TBL] [Abstract][Full Text] [Related]
39. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome.
Chu QD; Panu L; Holm NT; Li BD; Johnson LW; Zhang S
J Surg Res; 2010 Apr; 159(2):689-95. PubMed ID: 19500800
[TBL] [Abstract][Full Text] [Related]
40. Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.
Cai H; Li X; Li J; Ao L; Yan H; Tong M; Guan Q; Li M; Guo Z
Oncotarget; 2015 Dec; 6(42):44593-608. PubMed ID: 26527319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
